HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Givaudan believes Parsol 1789 data set "high" standard for monograph inclusion.

This article was originally published in The Rose Sheet

Executive Summary

GIVAUDAN BELIEVES PARSOL 1789 DATA SET "HIGH" STANDARD for inclusion in the tentative final monograph on sunscreens, Givaudan-Roure outside counsel Edward Basile (Washington, D.C. law firm King & Spalding) said at a March 6 "OTC feedback" meeting with FDA. Basile maintained that the data submitted by Givaudan for the UVA sunscreen ingredient Parsol 1789 (avobenzone) will establish "a very high standard, a very rigorous standard that other companies have to meet who want to get into the monograph."

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001413

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel